Finance

Lists
9926:HKG
Akeso Inc
HK$89.90
-5.72%
(-5.45) 1D
Aug 31, 4:08:46 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 9926...
Open
HK$93.60
High
HK$93.70
Low
HK$89.60
Mkt. cap
82.81B
Avg. vol.
0.00
Volume
14.10M
52-wk high
HK$159.80
52-wk low
HK$80.20
EPS
-HK$1.23
No. of employees
4K
Open
HK$93.60
High
HK$93.70
Low
HK$89.60
Mkt. cap
82.81B
Avg. vol.
0.00
Volume
14.10M
52-wk high
HK$159.80
52-wk low
HK$80.20
EPS
-HK$1.23
No. of employees
4K
Profile
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong. It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
About Akeso Inc
CEOMichelle Xia | Michelle Xia
Employees4.08K
FoundedMar 19, 2012
Headquarters-
SectorBiotechnology
Websiteakesobio.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
822.37M
822.37M
902.84M
902.84M
Cost of goods sold
191.35M
191.35M
232.59M
232.59M
Cost of revenue
191.35M
191.35M
232.59M
232.59M
Research and development expenses
421.91M
421.91M
391.66M
391.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
464.36M
464.36M
477.58M
477.58M
Operating expense
883.23M
883.23M
958.00M
958.00M
Total operating expenses
1.07B
1.07B
1.19B
1.19B
Operating income
-252.21M
-252.21M
-287.75M
-287.75M
Other non operating income
29.10M
29.10M
75.49M
75.49M
EBT including unusual items
-276.45M
-276.45M
-221.95M
-221.95M
EBT excluding unusual items
-276.19M
-276.19M
-226.43M
-226.43M
Income tax expense
-192.50K
-192.50K
1.68M
1.68M
Effective tax rate
0.07%
0.07%
-0.75%
-0.75%
Other operating expenses
-3.04M
-3.04M
88.75M
88.75M
Net income
-271.47M
-271.47M
-212.11M
-212.11M
Net profit margin
-33.01%
-33.01%
-23.49%
-23.49%
Earnings per share
-
-
-
-
Interest and investment income
84.42M
84.42M
74.56M
74.56M
Interest expense
-33.81M
-33.81M
-31.66M
-31.66M
Net interest expenses
50.61M
50.61M
42.90M
42.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
-187.68M
-187.68M
-227.30M
-227.30M
Gain or loss from assets sale
-1.00K
-1.00K
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps